tbuckley/cabot-search huggingface dataset:
Driver-target-drug algorithm in the interpretation of molecular cancer profiles.
Authors: Istvan Petak, Richard Schwab, Zsofia Binder, Eva Kocsis, Csilla Hegedűs, Zselyke Magyari, Andrea Kohanka, Gyorgy Keri
Journal: Journal of Clinical Oncology (2015)

e22069 Background: The standardized integration of preclinical and clinical evidences into the interpretation of multi-gene assays is more and more important in the clinical practice of medical oncologists. We aimed to develop a simple three-step algorithm for the decision support process of the selection of the best available targeted therapies linked to the highest available evidences. Methods: We analyzed the molecular profile of lung cancer tumors (N = 82) sequenced by next-generation sequencing (NGS) of a panel of 58 cancer-related genes (ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL, DDR2, CHEK2, PIK3R1, MAP2K1, JAK1, TGFBR2, PDGFRB, IGFR1) and FISH analysis of HER-2, ALK, RS1, c-MET, FGFR, PIK3CA, EGFR. Driver mutations were defined based on their frequency in the COSMIC database, functional data clustered into published preclinical evidence types (e.g. Evidence for exclusivity with other driver genes in the same signal transduction pathway etc.), and clinical evidence types (e.g. Evidence for association with worse prognosis etc.). Driver-Target associations were evaluated base on specific evidence types (decreased or increased sensitivity to specific inhibitors in case of certain drivers). Target-Drug associations were established based on preclinical and clinical evidences related to 260 compounds in clinical use or clinical development. Results: In 16% of patients we identified only non-functional polymorphic variants or were wild types for all genes. 48% contained 1 driver mutation, 23% 2 drivers, 8% 3 drivers, 5% 4 drivers. 91,4% of cases we found positive association and 40,9% of cases negative association between the molecular profile and at least one of the targeted compounds. Conclusions: The standardized Driver-Target-Drug interpretation algorithm is highly informative and can be easily integrated into a standardized evidence–based decision process of precision medicine.
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
Authors: Noha Abdel-Wahab, Houssein Safa, Ala Abudayyeh, Daniel H. Johnson, Van Anh Trinh, Chrystia M. Zobniw, Heather Lin, Michael K. Wong, Maen Abdelrahim, A. Osama Gaber, Maria E. Suarez-Almazor, Adi Diab
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Checkpoint inhibitors (CPIs) have revolutionized the treatment of cancer, but their use remains limited by off-target inflammatory and immune-related adverse events. Solid organ transplantation (SOT) recipients have been excluded from clinical trials owing to concerns about alloimmunity, organ rejection, and immunosuppressive therapy. Thus, we conducted a retrospective study and literature review to evaluate the safety of CPIs in patients with cancer and prior SOT. <h3>Methods</h3> Data were collected from the medical records of patients with cancer and prior SOT who received CPIs at The University of Texas MD Anderson Cancer Center from January 1, 2004, through March 31, 2018. Additionally, we systematically reviewed five databases through April 2018 to identify studies reporting CPIs to treat cancer in SOT recipients. We evaluated the safety of CPIs in terms of alloimmunity, immune-related adverse events, and mortality. We also evaluated tumor response to CPIs. <h3>Results</h3> Thirty-nine patients with allograft transplantation were identified. The median age was 63 years (range 14–79 years), 74% were male, 62% had metastatic melanoma, 77% received anti-PD-1 agents, and 59% had prior renal transplantation, 28% hepatic transplantation, and 13% cardiac transplantation. Median time to CPI initiation after SOT was 9 years (range 0.92–32 years). Allograft rejection occurred in 41% of patients (11/23 renal, 4/11 hepatic, and 1/5 cardiac transplantations), at similar rates for anti-CTLA-4 and anti-PD-1 therapy. The median time to rejection was 21 days (95% confidence interval 19.3–22.8 days). There were no associations between time since SOT and frequency, timing, or type of rejection. Overall, 31% of patients permanently discontinued CPIs because of allograft rejection. Graft loss occurred in 81%, and death was reported in 46%. Of the 12 patients with transplantation biopsies, nine (75%) had acute rejection, and five of these rejections were T cell-mediated. In melanoma patients, 36% responded to CPIs. <h3>Conclusions</h3> SOT recipients had a high allograft rejection rate that was observed shortly after CPI initiation, with high mortality rates. Further studies are needed to optimize the anticancer treatment approach in these patients.
Abstract 16103: Congenital Heart Defects Result From Accumulated Disturbance of Pathways that Regulate Heart Development
Authors: Douglas C Bittel, Nataliya Kibiryeva, Jennifer Marshall, Tara M Swanson, Michael Artman, James E O’Brien
Journal: Circulation (2016)

Introduction: Congenital heart defects (CHDs) are the most common birth defect and although studies of the developing vertebrate heart have provided a framework of regulatory control the underlying...
GS-10-A germline mutation in SEMA4D leads to a familial syndrome of sclerosing cholangitis
Authors: Xiaojun Jiang, Annika M Bergquist, Britt Sabina Petersen, Geetha Venkatesh, Jeff Mold, Jon Kristen Laerdahl, Sigrid Skånland, Kimia T Maleki, Martin Cornillet, Kjetil Tasken, Andre Franke, Tom Hemming Karlsen, Niklas Bjorkstrom, Espen Melum
Journal: Journal of Hepatology (2019)
Abstract 16212: Warranty Period of Zero Coronary Artery Calcium Score in Asymptomatic Korean Individuals
Authors: Ji-hyun Lee, Dong-hee Han, Bríain ó Hartaigh, Heidi Gransar, Su-Yeon Choi, Ji-dong Sung, James K Min, Hyuk-Jae Chang
Journal: Circulation (2015)

Introduction: Zero coronary artery calcium (CAC) is a reliable predictor of absent atherosclerosis and serves as a useful adjunct for identifying those at low risk. Despite this, the “warranty period” that displays the protective value associated with the absence of CAC towards experiencing a cardiovascular event among Asians is not well established. Hypothesis: To examine whether the absence of CAC displays a more favorable warranty period for all-cause death compared with the presence of CAC in a Korean cohort. Methods: A total of 48,215 asymptomatic Koreans (mean age: 54±8.8 years; 25% women) were enrolled and stratified by the absence or presence of CAC. Time to exceeding 1% of cumulative all-cause death was estimated in order to identify low-risk individuals. Hazard ratios (HR) with 95% confidence intervals (95% CI) for all-cause death were estimated according to prespecified cardiac risk factors and the presence of CAC. Results: In total, 30,605 (63.5%) individuals presented with a zero CAC. Across a median follow-up of 4.4 years (Interquartile range: 2.7-6.6 years), 415 (0.9%) individuals experienced the endpoint of all-cause death. For those with a zero CAC, the time to exceeding 1% risk was found to be 9 years, indicating a substantially longer warranty period compared with participants with a CAC&gt;0 (e.g., 5 year warranty period). The time to exceeding 1% risk tended to decline for individuals on the background of increasing CAC scores. For each of the other prespecified risk factor groups, a zero CAC provided a longer cumulative event free period than in the presence of any CAC. Cox regression analyses also revealed that the absence of CAC was independently associated with a lower risk of all-cause death in each of the respective risk factor groups when compared with CAC&gt;0. Conclusions: In a large cohort of asymptomatic Korean individuals, the absence of CAC evokes a strong protective effect against all-cause death as demonstrated by a longer warranty period.
Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer—Beyond the Misdiagnosis
Authors: Jian Xu, Zhiqian Hu, Haiyang Zhou
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Endoscopic full-thickness transoral outlet reduction with semicircumferential endoscopic submucosal dissection
Authors: Marcus Hollenbach, Lars Selig, Sylvia Lellwitz, Sebastian Beer, Jürgen Feisthammel, Jonas Rosendahl, Tiffany Schaumburg, Joachim Mössner, Albrecht Hoffmeister
Journal: Endoscopy (2019)

Abstract Background Endoscopic full-thickness transoral outlet reduction (efTOR) is a therapeutic option to reduce a dilated gastrojejunal anastomosis (GJA) after Roux-en-Y gastric bypass (RYGB). Mucosal ablation with argon plasma coagulation (APC) is usually performed to achieve tissue adaptation. However, rupture of sutures before scarring can lead to recurrent dilatation of the GJA. Here, we describe efTOR with a semicircumferential endoscopic submucosal dissection (ESD-efTOR) as an alternative to APC-efTOR. Methods We enrolled 41 patients with comparable baseline characteristics (APC-efTOR 26; ESD-efTOR 15). The main objectives were reduction in the GJA diameter and in ruptured sutures. Technical success, complications, total weight loss (TWL), and percentage of total and excess weight loss (%TWL and %EWL) at 3 and 12 months, were assessed. Results ESD-efTOR resulted in significantly fewer ruptured sutures (20 % vs. 69 %; P = 0.004) and a greater reduction in the GJA (major 20 % vs. 0 %; minor 54 % vs. 37 %; no reduction 13 % vs. 58 %; P = 0.02) after 3 months. Technical efficacy, examination time, and rate of complications were comparable. Conclusions ESD-efTOR resulted in a significantly greater reduction in the GJA diameter and a lower risk of ruptured sutures compared with APC-efTOR.
THU-442-Role of drug transporters in the chemoresistance of hepatoblastoma
Authors: Maitane Asensio, Elisa Lozano, candela cives, Juan Carrillo, Lorena Abete, Oscar Briz, Stefano Cairo, Jordi Bruix, Carolina Armengol, Jose Marin, Rocio IR Macias
Journal: Journal of Hepatology (2019)
SAT-096-Large spontaneous portosystemic shunt (SPSS) area is associated with hepatic encephalopathy and predicts mortality in liver cirrhosis
Authors: Michael Praktiknjo, Macarena Simón-Talero, Davide Roccarina, Javier Martinez, Katharina Lampichler, Anna Baiges, Low Gavin, Elba Llop, Martin Maurer, Alexander Zipprich, Michela Triolo, Geert Maleux, Rita Garcia Martinez, Annette Dam Fialla, Claus Dam, Judit Vidal Gonzalez, Majumdar Avik, Carmen Picón, Daniel Toth, Anna Darnell, Juan Abraldes, Marta López-Gómez, Guido Kukuk, Aleksander Krag, Rafael Bañares, Wim Laleman, Vincenzo La Mura, Cristina Ripoll, Annalisa Berzigotti, José Luis Calleja Panero, Puneeta Tandon, Virginia Hernandez-Gea, Thomas Reiberger, Agustin Albillos, Emmanuel Tsochatzis, Joan Genesca, Jonel Trebicka
Journal: Journal of Hepatology (2019)
FRI-343-NEDDylation inhibition as a new potential therapy of non-alcoholic fatty liver disease
Authors: Marina Serrano-Macia, Mikel Azkargorta, Jorge Simón, Fernando Lopitz Otsoa, Teresa Cardoso Delgado, David Fernández Ramos, Virginia Gutiérrez de Juan, Marta Varela-Rey, Naroa Goikoetxea, Pablo Fernández Tussy, Patricia Apichueta, Diego Saenz de Urturi, Xabier Buque, Paula Iruzubieta, Javier Crespo, Shelly C. Lu, José M. Mato, Felix Elortza, María Luz Martínez-Chantar
Journal: Journal of Hepatology (2019)
Quality of life of pediatric patients with medulloblastoma: Results from single regional cancer centre.
Authors: Pooja Nandwani Patel, Rakesh Vyas, Maitrik Mehta
Journal: Journal of Clinical Oncology (2015)

e21038 Background: Medulloblastoma is the most common malignant brain tumor in children, and approximately 70% of average-risk patients will survive long-term. The ultimate goal of treatment of pediatric medulloblastoma is not only to cure but have reasonable good quality of life. Methods: From January 2009 to December 2011, 100 pediatric patients of medulloblastoma were enrolled. The age range was from 3 to 14 years. All the patients went total or near total excision followed by craniospinal irradiation and chemotherapy. The follow up was in the range of 36 to 58 months. Along with the local control rates and recurrence site important quality of life issues like neurological deficits, endocrine deficits and behavioral and psychological issues were studied. At the mean follow up of 42 months, neurological deficits were found in 63% and endocrine deficits in 58%. In comparison with healthy controls, social functioning was rated by patients as quality of life dimension was most important affected. Younger children aged 3-9 years had comparatively more fall in IQ as compared to children older than 9 years. Female children had worse prognosis compared to male children. Patients and families were encouraged to continue schooling as it provides a comfort zone and hope which are healing experiences both for children and their families as well. Results: Local control rates at 4 year were 78%. Counseling and continuation of school resulted in better quality of life as compared to patients who couldn’t continue schooling. There were no significant predisposing parameters for neurological and endocrine deficits and conformal therapies didn’t have any role to play as patient inevitably needed craniospinal irradiation. Conclusions: As patients with medulloblastoma survive quality of life is an important concern. With limited resources and financial constraints counseling and continuation of schooling was encouraged which in a way helped a lot to improve quality of life to a good extent.
Building Trust Between the Government and Clinicians
Authors: Peter V. Lee, Donald Berwick, Christine A. Sinsky
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Update of the statements on biology and clinical impact of occult hepatitis B virus infection
Authors: Giovanni Raimondo, Stephen Locarnini, Teresa Pollicino, Massimo Levrero, Fabien Zoulim, Anna S. Lok, Jean-Pierre Allain, Thomas Berg, Antonio Bertoletti, Maurizia Rossana Brunetto, Raffaele Bruno, Ding-Shinn Chen, Nicola Coppola, Markus Cornberg, Antonio Craxì, Maura Dandri, Vito Di Marco, Carlo Ferrari, Giovanni Battista Gaeta, Dieter Glebe, Luca G. Guidotti, Anna Kramvis, Pietro Lampertico, Chengyao Li, Jake Liang, Alfredo Marzano, Thomas I. Michalak, Jean-Michel Pawlotsky, Daniele Prati, Massimo Puoti, Didier Samuel, Vincent Soriano, Giovanni Squadrito, Camille Sureau, Christian Trepo, Man-Fung Yuen
Journal: Journal of Hepatology (2019)

In October 2018 a large number of international experts with complementary expertise came together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI). The objectives of the workshop were to review the existing knowledge on OBI, to identify issues that require further investigation, to highlight both existing controversies and newly emerging perspectives, and ultimately to update the statements previously agreed in 2008. This paper represents the output from the workshop.
Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery for Left Main Disease
Authors: Rodrigo Modolo, Ply Chichareon, Norihiro Kogame, Ovidiu Dressler, Aaron Crowley, Ori Ben-Yehuda, John Puskas, Adrian Banning, David P. Taggart, A. Pieter Kappetein, Joseph A. Sabik, Yoshinobu Onuma, Gregg W. Stone, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2019)
FRI-442-Acute hepatic porphyria disease manifestations and daily life impacts in EXPLORE international, prospective, natural history study
Authors: Laurent Gouya, Manisha Balwani, D Montgomery Bissell, David Rees, Ulrich Stölzel, John Phillips, Raili Kauppinen, Janneke Langendonk, Robert Desnick, Jean Charles Deybach, Herbert Bonkovsky, Charles Parker, Hetanshi Naik, Michael Badminton, Penelope Stein, Elisabeth Minder, Jerzy Windyga, Pavel Martasek, Maria Domenica Cappellini, Paolo Ventura, Eliane Sardh, Pauline Harper, Sverre Sandberg, Aasne Aarsand, Felix Alegre, Aneta Ivanova, Neila Talbi, John Ko, Dalia Cahana-Amitay, Amy Chan, Quinn Dinh, Craig Penz, Amy Simon, Tim Lin, Karl Anderson
Journal: Journal of Hepatology (2019)
SAT-098-Transjugular intrahepatic portosystematic shunt with 7 mm covered stent reduces hepatic encephalopathy without losing shunt function for prevention of portal hypertensive rebleeding
Authors: Xiaolong Qi, Yifan Wu, Chuan Liu, Zhendong Yue, Hongwei Zhao, Lei Wang, Xiaoxue Du, Fuliang hE, Fuquan Liu
Journal: Journal of Hepatology (2019)
Permanent pleural catheter (PPC) for malignant pleural effusion (PE) in advanced non-small cell lung cancer (NSCLC)
Authors: M. Martinez Kareaga, N. Urbieta-Macazaga, C. Sanchez-Vieco, L. Tomás-López, I. Intxaurbe-Etxebarria, B. Mareque, N. Torrego, A. Narro, L. Puntí, I. Guillen
Journal: Annals of Oncology (2019)

Background: Pleural effusion (PE) is a relatively frequent complication in patients (p) with advanced NSCLC that causes refractory symptoms such as pain and dyspnea. These patients frequently need repeated thoracocentesis to relieve symptoms. Methods: From May 2008 to September 2018, 30 consecutive patients of our hospital with advanced NSCLC who overwent to PPC implantation were retrospectively evaluated. Baseline characteristics, acute and late complications and outcome were retrospectively collected. Overall survival (OS) was calculated from the date of the PPC implantation to the date of death. Results: Thirty patients were evaluated, 20 were male and 10 female. All patients were death at the cut-off date, the 1st October 2018. Median age at PPC implantation was 66y (range: 47-91) and 80% presented ECOG PS 2. Adenocarcinoma was the most frequent histology (22p). Mean hospital stay was 7 days (range 1-28). Mean catheter duration was 60 days (range 3-181). Median OS was 14.3 weeks (IC 95%, range 1.3-59.1). Four patients (13%) suffered an acute complication: 1 pleuro-cutaneus fistula, 1 empyema, 1 hematoma and 1 needed surgical intervention because the catheter guided was at pleural cavity. After hospital discharge, one p presented a complication, with pleural liquid exit pericatheter. Twenty-five p (83%) presented clinical relief and 11p (37%) received chemotherapy after PPC implantation. Citology of pleural liquid was performed in 23p (77%) and resulted positive for malignancy in 14 cases. Conclusions: PPC implantation is a safe technique that can cause symptomatic relief in most patients with malignant pleural effusion. However, mean catheter duration and survival after PPC implantation are still low. Therefore a better selection of patients is mandatory. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
PS-027-The LLT1-CD161 interaction: An important inhibitory interaction for NK cells in cirrhosis
Authors: Naveenta Kumar, Fouzia Sadiq, Sujit Mukherjee, Wafa Khamri, Fanny Lebossé, Ameet Dhar, Marco Purbhoo, Robert D. Goldin, Mark Thursz, Harry Antoniades, Salim Khakoo
Journal: Journal of Hepatology (2019)
Myeloid‐derived suppressor cells: Roles and relations with Th2, Th17, and Treg cells in asthma
Authors: Qingdong Guan, Bin Yang, Richard J. Warrington, Steven Mink, Chrystyna Kalicinsky, Allan B. Becker, Elinor Simons, Zhikang Peng
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Response to Comment on Johnson et al. Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life. Diabetes Care 2019;42:69–76
Authors: Stephanie R. Johnson, Hannah E. Carter, Paul Leo, Samantha A. Hollingworth, Elizabeth A. Davis, Timothy W. Jones, Louise S. Conwell, Mark Harris, Matthew A. Brown, Nicholas Graves, Emma L. Duncan
Journal: Diabetes Care (2019)

We thank Estrella and Simmons (1) for their letter regarding implications and limitations of our study (2).

We agree that most of the cost and health benefits from identifying maturity-onset diabetes of the young (MODY) mutations in children with diabetes is due to conversion from insulin to oral hypoglycemic agents, as discussed in our article. Further, we agree that conversion is not always possible, although, as illustrated in their case, substantial reduction in dose may be possible even if insulin cannot be ceased entirely. As shown in Table 1 and Fig. 2, our sensitivity analysis tested for uncertainty in conversion rates, varying this parameter from 50% to 100% (based on limited published data); routine testing remained beneficial within this range.

We agree …
2018 Ebola virus disease outbreak in Équateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation
Authors: Placide Mbala-Kingebeni, Catherine B Pratt, Michael R Wiley, Moussa M Diagne, Sheila Makiala-Mandanda, Amuri Aziza, Nicholas Di Paola, Joseph A Chitty, Mamadou Diop, Ahidjo Ayouba, Nicole Vidal, Ousmane Faye, Oumar Faye, Stormy Karhemere, Aaron Aruna, Justus Nsio, Felix Mulangu, Daniel Mukadi, Patrick Mukadi, John Kombe, Anastasie Mulumba, Sophie Duraffour, Jacques Likofata, Elisabeth Pukuta, Katie Caviness, Maggie L Bartlett, Jeanette Gonzalez, Timothy Minogue, Shanmuga Sozhamannan, Stephen M Gross, Gary P Schroth, Jens H Kuhn, Eric F Donaldson, Eric Delaporte, Mariano Sanchez-Lockhart, Martine Peeters, Jean-Jacques Muyembe-Tamfum, Amadou Alpha Sall, Gustavo Palacios, Steve Ahuka-Mundeke
Journal: The Lancet Infectious Diseases (2019)